NCT06019533 is a Phase 3 clinical trial of LVDS in Contraception, sponsored by Chemo Research.

Who is sponsoring NCT06019533?

NCT06019533 is sponsored by Chemo Research.

What drugs are being tested in NCT06019533?

Interventions in NCT06019533: LVDS.

What condition does NCT06019533 study?

NCT06019533 studies Contraception.

Is NCT06019533 still recruiting?

NCT06019533 is currently active, enrolled. Last updated 21 February 2025.

Last reviewed 2025-02-21 · How we verify

NCT06019533

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial on Contraceptive Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 Cycles

Active, enrolled Phase 3 Last updated 21 February 2025

What this trial tests

Phase 3 trial testing LVDS in Contraception in 750 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 August 2023

Primary endpoint
30 April 2025

30 April 2026

Quick facts

Lead sponsor	Chemo Research
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	750
Start date	9 August 2023
Primary completion	30 April 2025
Estimated completion	30 April 2026
Sites	1 location across Spain

Drugs / interventions tested

LVDS

Conditions studied

Contraception — all drugs for Contraception →

Sponsor

Chemo Research

Who can join

Adults 15 to 45, female only, with Contraception. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicentre, single arm phase III trial to assess the pearl index of LVDS. The trial lasts 13 cycles.The assessments include (but are not limited to) recording demographic data, pregnancy tests, gynaecological examinations, laboratory tests and a quality of life questionnaire. Adolescents will undergo DXA scans to measure bone mineral density (at selected sites only). The women will be provided with an e-diary app for their smartphone, to record IP use and vaginal bleeding.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Contraception

Currently open trials in the same condition.

NCT07365904 — Investigating Ovulation Inhibition for Use as a Contraceptive · Phase 2 · recruiting
NCT07437495 — Women's Knowledge of Contraception During the Postpartum Period · active not recruiting
NCT06823037 — Hormonal Contraception Access Through Pharmacist Prescribing Implementation · NA · recruiting
NCT07326007 — Verbal Analgesia Versus Standard Technique for Pain Control During Copper T380A Intrauterine Device Insertion in Women W · NA · recruiting
NCT05910580 — Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06019533 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chemo Research
Last refreshed: 21 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06019533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing